Nuvelo Discontinues Factor VIIa Inhibitor To Focus On Alfimeprase
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of the realignment, Nuvelo will cut its work force by 30 percent and reduce annual expenses by $15 million.